Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
18.74
-0.85 (-4.34%)
At close: Jan 14, 2025, 4:00 PM
18.61
-0.13 (-0.69%)
After-hours: Jan 14, 2025, 7:17 PM EST
Denali Therapeutics Employees
Denali Therapeutics had 445 employees as of December 31, 2023. The number of employees increased by 18 or 4.22% compared to the previous year.
Employees
445
Change (1Y)
18
Growth (1Y)
4.22%
Revenue / Employee
n/a
Profits / Employee
-$960,658
Market Cap
2.70B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
DNLI News
- 5 days ago - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains - Seeking Alpha
- 8 days ago - Denali Therapeutics ALS drug fails in mid-stage trial - Reuters
- 8 days ago - Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire
- 11 days ago - Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga
- 2 months ago - Denali Has A Neurodegenerative Edge Despite Market Skepticism - Seeking Alpha
- 2 months ago - Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) - GlobeNewsWire
- 5 months ago - Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology - Seeking Alpha